7 research outputs found

    Polimorfizm genu oksydoreduktazy cytochromu P450 a farmakokinetyka pantoprazolu u zdrowych ochotników

    Get PDF
    Genetycznie uwarunkowana aktywność enzymów metabolizujących leki może mieć znaczenie dla bezpieczeństwa i skuteczności leczenia. We wcześniejszych badaniach wykazano, że na aktywność enzymatyczną CYP2C19 może wpływać nie tylko polimorfizm genu kodującego ten cytochrom, lecz także zawartość reduktazy cytochromu P450 (POR) w mikrosomach ludzkich hepatocytów. Ludzki gen POR wykazuje dużą zmienność, a allel POR*28 jest związany ze zwiększoną aktywnością reduktazy, co w konsekwencji może prowadzić do zwiększonej aktywności układu CYP P450, w tym enzymu CYP2C19. Celem badania było określenie związku pomiędzy polimorfizmem genu POR a parametrami farmakokinetycznymi pantoprazolu, substratu CYP2C19 w grupie zdrowych ochotników. W analizie uwzględniono także warianty genu CYP2C19. U 30 osób, u których wykonano badanie pod kątem występowania jednonukleotydowych polimorfizmów: rs4244285 (681G>A, CYP2C19*2), rs12248560 (-806C>T, CYP2C19*17) oraz rs1057868 (31696C>T, POR*28). Stężenia pantoprazolu w osoczu zmierzono metodą wysokosprawnej chromatografii cieczowej w ciągu 8 godz. od przyjęcia pojedynczej doustnej dawki leku (40 mg). Nie stwierdzono istotnych różnic w stężeniu pantoprazolu pomiędzy osobami o różnych genotypach POR (*1/*1, *1/*28 i *28/*28). Analiza wieloczynnikowa wykazała, że genotyp CYP2C19 istotnie wpływał na wartość wszystkich analizowanych parametrów farmakokinetycznych (p < 0.05), podczas gdy genotyp POR nie był istotnie związany z żadnym z nich. Wyniki badania wskazują, że polimorfizm genu POR nie wpływa istotnie na farmakokinetykę pantoprazolu.It has recently been demonstrated that CYP2C19 activity may be influenced not only by CYP2C19 polymorphism, but also cytochrome P450 oxidoreductase (POR) protein abundance in human liver microsomes. The human POR gene is highly polymorphic and a common POR*28 allele is associated with increased POR activity, which may result in increased CYP P450 activity (including CYP2C19). The aim of the current study was to evaluate the association between POR and CYP2C19 polymorphisms and CYP2C19 substrate pharmacokinetics, i.e. pantoprazole, in Polish Caucasian healthy volunteers. The study enrolled 30 subjects, genotyped for rs4244285 (681G>A, CYP2C19*2), rs12248560 (-806C>T, CYP2C19*17) and rs1057868 (31696C>T, POR*28). Pantoprazole concentration in plasma was determined by validated highperformance liquid-chromatography method 1 h, 2 h, 3 h, 4 h, 6 h and 8 h after a single oral 40 mg dose of the drug. No significant differences in the drug concentrations between POR*1/*1, POR*1/*28 and POR*28/*28 carriers were observed. Multivariate analysis revealed that the CYP2C19 genotype significantly influenced all the investigated pharmacokinetic parameters (p < 0.05), while the POR genotype was not associated with any of the parameters. The results of the current study suggest that POR polymorphism does not significantly influence pantoprazole pharmacokinetics

    Pharmacokinetics of levodopa and 3-O-methyldopa in parkinsonian patients treated with levodopa and ropinirole and in patients with motor complications

    No full text
    Parkinson’s disease (PD) is a progressive, neurodegenerative disorder primarily affecting dopaminergic neuronal systems, with impaired motor function as a consequence. The most effective treatment for PD remains the administration of oral levodopa (LD). Long-term LD treatment is frequently associated with motor fluctuations and dyskinesias, which exert a serious impact on a patient’s quality of life. The aim of our study was to determine the pharmacokinetics of LD: used as monotherapy or in combination with ropinirole, in patients with advanced PD. Furthermore, an effect of ropinirole on the pharmacokinetics of 3-OMD (a major LD metabolite) was assessed. We also investigated the correlation between the pharmacokinetic parameters of LD and 3-OMD and the occurrence of motor complications. Twenty-seven patients with idiopathic PD participated in the study. Thirteen patients received both LD and ropinirole, and fourteen administered LD monotherapy. Among 27 patients, twelve experienced fluctuations and/or dyskinesias, whereas fifteen were free of motor complications. Inter- and intra-individual variation in the LD and 3-OMD concentrations were observed. There were no significant differences in the LD and 3-OMD concentrations between the patients treated with a combined therapy of LD and ropinirole, and LD monotherapy. There were no significant differences in the LD concentrations in patients with and without motor complications; however, plasma 3-OMD levels were significantly higher in patients with motor complications. A linear one-compartment pharmacokinetic model with the first-order absorption was adopted for LD and 3-OMD. Only mean exit (residence) time for 3-OMD was significantly shorter in patients treated with ropinirole. Lag time, V/F, CL/F and t(max) of LD had significantly lower values in patients with motor complications. On the other hand, AUC were significantly higher in these patients, both for LD and 3-OMD. 3-OMD C(max) was significantly higher in patients with motor complications as well. Our results showed that ropinirole does not influence LD or 3-OMD concentrations. Higher 3-OMD levels play a role in inducing motor complications during long-term levodopa therapy

    CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers

    Get PDF
    OBJECTIVES: Pantoprazole is metabolized by cytochrome P450 2 C19, which shows genetic polymorphism. The effect of CYP2C19 polymorphism on single-dose pharmacokinetics of oral pantoprazole in healthy volunteers was evaluated. METHODS: Pantoprazole pharmacokinetics was determined in 32 healthy volunteers after a 40-mg single oral dose of the drug. RESULTS: Carriers of CYP2C19*2/*2 (n = 2) were characterized by higher, starting from 3.5 h post dose, plasma concentrations of pantoprazole in comparison to wild-type (CYP2C19*1/*1, n = 6) volunteers. In subjects with CYP2C19*17/*17 genotype (n = 6) significantly lower plasma concentrations of the drug vs CYP2C19*1/*1 carriers, were observed from 3.0 h after oral pantoprazole administration. Carriers of CYP2C19*1/*17 (n = 6) and CYP2C19*2/*17 (n = 6) displayed concentration–time profiles comparable to wild-type subjects. CYP2C19*2/*2 volunteers showed a decrease in terminal elimination rate constant (λ(z)) by 83.3%, prolongation of terminal half-life (t(½)) by 572%, a rise in area under the concentration–time curve (AUC) and mean residence time (MRT) by 506% and 259% respectively. Heterozygotes, i.e.. CYP2C19*1/*2 vs CYP2C19*1/*1 were characterized by higher AUC (4.38 ± 1.00 mg⋅h/L vs 3.00 ± 1.02 mg⋅h/L, p < 0.05) and C(max) (2.13 ± 0.42 mg/L vs 1.61 ± 0.35 mg/L, p < 0.05) respectively. A significant reduction in MRT (3.83 ± 0.82 h vs 2.73 ± 0.23 h, p < 0.05) in carriers of CYP2C19*17/*17 vs CYP2C19*1/*1 genotypes was observed. Population modeling confirmed the influence of *1/*2, *2/*2, and *17/*17 genotypes on the pharmacokinetics of pantoprazole. The lowest population oral clearance was assessed in the carriers of genotype *2/*2 (3.68 L/h) and the highest value in subjects with genotype *17/*17 (31.13 L/h). CONCLUSION: These data suggest that CYP2C19 polymorphism is an important determinant of pantoprazole pharmacokinetics

    Permeability of Ibuprofen in the Form of Free Acid and Salts of L-Valine Alkyl Esters from a Hydrogel Formulation through Strat-M™ Membrane and Human Skin

    No full text
    This paper aimed to evaluate the effect of vehicle and chemical modifications of the structure of active compounds on the skin permeation and accumulation of ibuprofen [IBU]. In vitro permeation experiments were performed using human abdominal skin and Strat-M™ membrane. The HPLC method was used for quantitative determinations. The formulations tested were hydrogels containing IBU and its derivatives and commercial gel with ibuprofen. The results obtained indicate that Celugel® had an enhancing effect on the skin penetration of IBU. The average cumulative mass of [IBU] after 24 h permeation test from Celugel® formulation through human skin was over 3 times higher than for the commercial product. Three ibuprofen derivatives containing [ValOiPr][IBU], [ValOPr][IBU], and [ValOBu][IBU] cation were evaluated as chemical penetration enhancers. The cumulative mass after 24 h of penetration was 790.526 ± 41.426, 682.201 ± 29.910, and 684.538 ± 5.599 μg IBU cm−2, respectively, compared to the formulation containing unmodified IBU-429.672 ± 60.151 μg IBU cm−2. This study demonstrates the perspective of the transdermal hydrogel vehicle in conjunction with the modification of the drug as a potential faster drug delivery system

    Epilobium angustifolium L. Extracts as Valuable Ingredients in Cosmetic and Dermatological Products

    No full text
    Epilobium angustifolium L. is a popular and well-known medicinal plant. In this study, an attempt to evaluate the possibility of using this plant in preparations for the care and treatment of skin diseases was made. The antioxidant, antiaging and anti-inflammatory properties of ethanolic extracts from Epilobium angustifolium (FEE) were assessed. Qualitative and quantitative evaluation of extracts chemically composition was performed by gas chromatography with mass spectrometry (GC-MS) and high-performance liquid chromatography (HPLC). The total polyphenol content (TPC) of biologically active compounds, such as the total content of polyphenols (TPC), flavonoids (TFC), and assimilation pigments, as well as selected phenolic acids, was assessed. FEE was evaluated for their anti-inflammatory and antiaging properties, achieving 68% inhibition of lipoxygenase activity, 60% of collagenase and 49% of elastase. FEE also showed high antioxidant activity, reaching to 87% of free radical scavenging using 2,2-diphenyl-1-picrylhydrazyl (DPPH) and 59% using 2,2′-azinobis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS). Additionally, in vitro penetration studies were performed using two vehicles, i.e., a hydrogel and an emulsion containing FEE. These studies showed that the active ingredients contained in FEE penetrate through human skin and accumulate in it. The obtained results indicate that E. angustifolium may be an interesting plant material to be applied as a component of cosmetic and dermatological preparations with antiaging and anti-inflammatory properties
    corecore